Biota Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Published: Feb, 2014 | Pages: 45 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Biota Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Biota Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Biota Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Biota Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Biota Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Biota Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Biota Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

- Evaluate Biota Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Biota Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Biota Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Biota Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biota Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Biota Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Biota Pharmaceuticals, Inc. Snapshot 6
Biota Pharmaceuticals, Inc. Overview 6
Key Information 6
Key Facts 6
Biota Pharmaceuticals, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Biota Pharmaceuticals, Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Biota Pharmaceuticals, Inc. - Pipeline Products Glance 13
Biota Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Biota Pharmaceuticals, Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Biota Pharmaceuticals, Inc. - Drug Profiles 16
vapendavir 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
CDI-538 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
CDI-936 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Clostridium Difficile Program 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Flunet 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Gyrase Program 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
GyrB/ParE Antibiotic 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
HCV-NN Program 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
PPAT Inhibitor Program 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
RSV Fusion Inhibitors 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Small Molecule to Inhibit FtsZ for Bacterial Infections 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecule-1 to Inhibit Topoisomerases II and Topoisomerase IV for Infectious Diseases 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecule-2 to Inhibit Topoisomerases II and Topoisomerase IV for Infectious Diseases 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
EnteroVAX 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Biota Pharmaceuticals, Inc. - Pipeline Analysis 31
Biota Pharmaceuticals, Inc. - Pipeline Products by Target 31
Biota Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 32
Biota Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 33
Biota Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 34
Biota Pharmaceuticals, Inc. - Recent Pipeline Updates 35
Biota Pharmaceuticals, Inc. - Dormant Projects 39
Biota Pharmaceuticals, Inc. - Discontinued Pipeline Products 40
Discontinued Pipeline Product Profiles 40
BTA-9881 40
BTAC-286 40
StaphVAX 40
Biota Pharmaceuticals, Inc. - Company Statement 41
Biota Pharmaceuticals, Inc. - Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 45
Disclaimer 45

List of Tables
Biota Pharmaceuticals, Inc., Key Information 6
Biota Pharmaceuticals, Inc., Key Facts 6
Biota Pharmaceuticals, Inc. - Pipeline by Indication, 2014 9
Biota Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 11
Biota Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 12
Biota Pharmaceuticals, Inc. - Phase II, 2014 13
Biota Pharmaceuticals, Inc. - Preclinical, 2014 14
Biota Pharmaceuticals, Inc. - Discovery, 2014 15
Biota Pharmaceuticals, Inc. - Pipeline by Target, 2014 31
Biota Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 32
Biota Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 33
Biota Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 34
Biota Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 35
Biota Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 39
Biota Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 40
Biota Pharmaceuticals, Inc., Other Locations 43